Abstract
An inborn error of metabolism is caused by a genetic inability to produce the full complement of a given functioning protein in its normal configuration. Although many of these disorders are rare, they often produce devastating ocular manifestations. Because of the severity and the high incidence of these ocular manifestations, the ophthalmologist is often involved in the care of these patients. In addition, the ophthalmologist is often asked to play an early role in order to detect subtle, early, and occasionally pathognomonic lesions to aid in the diagnosis of these rare disorders. This chapter will discuss those inborn errors of metabolism that may have an effect on both retinal function and appearance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Guo, S.Q., Reinecke, R.D., Fendick, M., Calhoun, J.H.: Visual pathway abnormalities in albinism and infantile nystagmus: VECPs and stereoacuity measurements. J. Pediatr. Ophthalmol. Strabismus. 26, 97–104 (1989)
O’Donnell Jr., F.E., Green, W.R., Fleischman, J.A., Hambrick, G.W.: X-linked ocular albinism in Blacks. Ocular albinism cum pigmento. Arch. Ophthalmol. 96, 1189–1192 (1978)
Lee, S.T., Nicholls, R.D., Schnur, R.E., et al.: Diverse mutations of the P gene among African-Americans with type II (tyrosinase-positive) oculocutaneous albinism (OCA2). Hum. Mol. Genet. 3, 2047–2051 (1994)
Lee, S.T., Nicholls, R.D., Bundey, S., Laxova, R., Musarella, M., Spritz, R.A.: Mutations of the P gene in oculocutaneous albinism, ocular albinism, and Prader-Willi syndrome plus albinism. N. Engl. J. Med. 330, 529–534 (1994)
Boissy, R.E., Zhao, H., Oetting, W.S., et al.: Mutation in and lack of expression of tyrosinase-related protein-1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as “OCA3”. Am. J. Hum. Genet. 58, 1145–1156 (1996)
Charles, S.J., Moore, A.T., Grant, J.W., Yates, J.R.: Genetic counselling in X-linked ocular albinism: clinical features of the carrier state. Eye 6(pt 1), 75–79 (1992)
Hermansky, F., Pudlak, P.: Albinism associated with hemorrhagic diathesis and unusual pigmented reticular cells in the bone marrow: report of two cases with histochemical studies. Blood 14, 162–169 (1959)
Simon, J.W., Adams, R.J., Calhoun, J.H., Shapiro, S.S., Ingerman, C.M.: Ophthalmic manifestations of the Hermansky–Pudlak syndrome (oculocutaneous albinism and hemorrhagic diathesis). Am. J. Ophthalmol. 93, 71–77 (1982)
Witkop Jr., C.J., Hill, C.W., Desnick, S., et al.: Ophthalmologic, biochemical, platelet, and ultrastructural defects in the various types of oculocutaneous albinism. J. Invest. Dermatol. 60, 443–456 (1973)
Witkop, C.J., Nunez Babcock, M., Rao, G.H., et al.: Albinism and Hermansky–Pudlak syndrome in Puerto Rico. Bol. Asoc. Med. P. R. 82, 333–339 (1990)
Apkarian, P., Tijssen, R.: Detection and maturation of VEP albino asymmetry: an overview and a longitudinal study from birth to 54 weeks. Behav. Brain Res. 49, 57–67 (1992)
Simell, O., Takki, K.: Raised plasma-ornithine and gyrate atrophy of the choroid and retina. Lancet 1, 1031–1033 (1973)
Kaiser-Kupfer, M.I., Kuwabara, T., Askanas, V., et al.: Systemic manifestations of gyrate atrophy of the choroid and retina. Ophthalmology 88, 302–306 (1981)
McCulloch, J.C., Arshinoff, S.A., Marliss, E.B., Parker, J.A.: Hyperornithinemia and gyrate atrophy of the choroid and retina. Ophthalmology 85, 918–928 (1978)
Takki, K.K., Milton, R.C.: The natural history of gyrate atrophy of the choroid and retina. Ophthalmology 88, 292–301 (1981)
Wilson, D.J., Weleber, R.G., Green, W.R.: Ocular clinicopathologic study of gyrate atrophy. Am. J. Ophthalmol. 111, 24–33 (1991)
Kaiser-Kupfer, M.I., Caruso, R.C., Valle, D.: Gyrate atrophy of the choroid and retina. Long-term reduction of ornithine slows retinal degeneration. Arch. Ophthalmol. 109, 1539–1548 (1991)
Kennaway, N.G., Stankova, L., Wirtz, M.K., Weleber, R.G.: Gyrate atrophy of the choroid and retina: characterization of mutant ornithine aminotransferase and mechanism of response to vitamin B6. Am. J. Hum. Genet. 44, 344–352 (1989)
Read, J., Goldberg, M.F., Fishman, G., Rosenthal, I.: Nephropathic cystinosis. Am. J. Ophthalmol. 76, 791–796 (1973)
Sanderson, P.O., Kuwabara, T., Stark, W.J., Wong, V.G., Collins, E.M.: Cystinosis. A clinical, histopathologic, and ultrastructural study. Arch. Ophthalmol. 91, 270–274 (1974)
Kaiser-Kupfer, M.I., Chan, C.C., Rodrigues, M., Datiles, M.B., Gahl, W.A.: Nephropathic cystinosis: immunohistochemical and histopathologic studies of cornea, conjunctiva and iris. Curr. Eye Res. 6, 617–622 (1987)
Wong, V.G., Lietman, P.S., Seegmiller, J.E.: Alterations of pigment epithelium in cystinosis. Arch. Ophthalmol. 77, 361–369 (1967)
Markello, T.C., Bernardini, I.M., Gahl, W.A.: Improved renal function in children with cystinosis treated with cysteamine. N. Engl. J. Med. 328, 1157–1162 (1993)
Kaiser-Kupfer, M.I., Gazzo, M.A., Datiles, M.B., Caruso, R.C., Kuehl, E.M., Gahl, W.A.: A randomized placebo-controlled trial of cysteamine eye drops in nephropathic cystinosis. Arch. Ophthalmol. 108, 689–693 (1990)
Purdue, P.E., Lumb, M.J., Fox, M., et al.: Characterization and chromosomal mapping of a genomic clone encoding human alanine:glyoxylate aminotransferase. Genomics 10, 34–42 (1991)
Cramer, S.D., Ferree, P.M., Lin, K., Milliner, D.S., Holmes, R.P.: The gene encoding hydroxypyruvate reductase (GRHPR) is mutated in patients with primary hyperoxaluria type II. Hum. Mol. Genet. 8, 2063–2069 (1999)
Small, K.W., Letson, R., Scheinman, J.: Ocular findings in primary hyperoxaluria. Arch. Ophthalmol. 108, 89–93 (1990)
Emery, J.M., Green, W.R., Wyllie, R.G., Howell, R.R.: GM1-gangliosidosis. Ocular and pathological manifestations. Arch. Ophthalmol. 85, 177–187 (1971)
Cogan, D.G., Chu, F.C., Barranger, J., Gregg, R.: Macula halo syndrome. Trans. Am. Ophthalmol. Soc. 80, 184–192 (1982)
Weingeist, T.A., Blodi, F.C.: Fabry’s disease: ocular findings in a female carrier. A light and electron microscopy study. Arch. Ophthalmol. 85, 169–176 (1971)
Tieu, P.T., Bach, G., Matynia, A., Hwang, M., Neufeld, E.F.: Four novel mutations underlying mild or intermediate forms of alpha-L-iduronidase deficiency (MPS I S and MPS I H/S). Hum. Mutat. 6, 55–59 (1995)
Cleary, M.A., Wraith, J.E.: The presenting features of mucopolysaccharidosis type I H (Hurler syndrome). Acta Paediatr. 84, 337–339 (1995)
Kaplan, D.: Classification of the mucopolysaccharidoses based on the pattern of mucopolysacchariduria. Am. J. Med. 47, 721–729 (1969)
Gullingsrud, E.O., Krivit, W., Summers, C.G.: Ocular abnormalities in the mucopolysaccharidoses after bone marrow transplantation. Longer follow-up. Ophthalmology 105, 1099–1105 (1998)
Runge, P., Muller, D.P., McAllister, J., Calver, D., Lloyd, J.K., Taylor, D.: Oral vitamin E supplements can prevent the retinopathy of abetalipoproteinaemia. Br. J. Ophthalmol. 70, 166–173 (1986)
Federico, A., Battistini, S., Ciacci, G., et al.: Cherry-red spot myoclonus syndrome (type I sialidosis). Dev. Neurosci. 13, 320–326 (1991)
Lou, J.S., Snyder, R., Griggs, R.C.: Refsum’s disease: long term treatment preserves sensory nerve action potentials and motor function. J. Neurol. Neurosurg. Psychiatr. 62, 671–672 (1997)
Acknowledgement
Photographs courtesy of Richard Alan Lewis, M.D., M.S.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Berlin Heidelberg
About this chapter
Cite this chapter
Olitsky, S.E. (2011). Inborn Errors of Metabolism Affecting the Retina. In: Reynolds, J., Olitsky, S. (eds) Pediatric Retina. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12041-1_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-12041-1_6
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-12040-4
Online ISBN: 978-3-642-12041-1
eBook Packages: MedicineMedicine (R0)